news and
publications
press releases | publications and abstracts | in the news
Publications and abstracts
Publications
- Potent Pleiotropic Anti-angiogenic Effects of TM601, a Synthetic Chlorotoxin Peptide
Jacoby D, Dyskin E, Yalcin M, Kesavan K, Dahlberg W, Ratliff J, Johnson E, Mousa S. Anticancer Research. 2010; 30:39-46.
- Annexin A2 Is a Molecular Target for TM601, a Peptide with Tumor-targeting and Anti-angiogenic Effects
Kesavan K, Ratliff J, Johnson E, Dahlberg W, Asara J, Misra P, Frangioni J, Jacoby D. Journal of Biological Chemistry. 2010; 285(7).
- Inhibition of tumor cell invasion with chlorotoxin-bound superparamagnetic nanoparticles
Veiseh O, Gunn JW, Kievit FM et al. Small. 2009; 5:256-64.
- A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells
Veiseh O, Kievit FM, Gunn JW, Ratner BD, Shang M. Biomaterials. 2009; 30(4): 649-57.
- Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles
Sun C, Fan C, Stephen Z et al. Nanomedicine. 2008; 3: 495-505.
- An unexpected role for ion channels in brain tumor metastasis
Sontheimer H. Exp Biol Med. 2008; 233: 779-791.
- Specific targeting of gliomas with multifunctional superparamagnetic iron oxide nanoparticle optical and magnetic resonance imaging contrast agents.
Meng X, Wan J, Jing M, Zhao S, Cai W, Liu E. Acta Pharmacol Sin. 2007; 28 (12): 2019-2026.
- In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes.
Sun C, Veiseh O, Gunn J et al. Small. 2008; 4(3):372-9.
- Tumor Paint: A Chlorotoxin:Cy5.5 Bioconjugate for intraoperative visualization of cancer foci.
Veiseh M, Gabikian P, Bahrami S et al. Cancer Res. 2007; 64(14):6882-6888.
- Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM601)
Mamelak AM, Jacoby DB. Expert Opinion. 2007; 4(2):175-186.
- Phase I Single-Dose Study of Intracavitary-Administered Iodine-131TM601 in Adults with Recurrent High-Grade Glioma
Mamelak AN, Rosenfeld S, Buscholz R, et al. J Clin Oncol. 2006; 24(22):3644-3650.
- Imaging Glioma Extent with 131I-TM601
Hockaday DC, Shen S, Fiveash J, et al. J Nucl Med. 2005; 46: 580-586.
- Optical and MRI Multifunctional Nanoprobe for Targeting Gliomas
Veiseh O, Sun C, Gunn J et al. Nano Letters. 2005; 5(6):1003-1008.
- Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin
Lyons S, O'Neal J, Sontheimer H. GLIA. 2002; 39:162-173.
- Direct Interaction with Contactin Targets Voltage-gated Sodium Channel Nav1.9/NaN to the Cell Membrane
Liu C, Dib-Hajj S, Black J, Greenwood J, Lian Z, Waxman S. J Biological Chem. 2001; 276(49): 46553-46561.
Abstracts
- Identification and validation of Annexin A2 as novel target for TM601, a tumor-targeting peptide with anti-angiogenic properties.
K Kesavan, J Ratliff, E Johnson, W Dahlberg, D.B. Jacoby
Presented - AACR EORTC NCI Boston MA 2009
- A Randomized Phase II Study of Intracavitary 131ITM601 in the Treatment of Recurrent Malignant Glioma.
J.B. Fiveash, L.B. Nabors, B. Badie, A.N. Mamelak, R. Costello, O’Neill
- Single versus Multiple Dose Radiopharmaceutical Injections: Dosimetry Analysis of Intracavitary 131I-TM601 in High-grade Glioma Patients.
S Shen, LB Nabors, JJ Raizer, JB Fiveash, S Spies, R Costello, AM O'Neill.
- A phase I evaluation of intravenous TM601 in recurrent glioblastoma: Use of perfusion MRI to monitor antiangiogenic effects.
Akella NS, Nabors LB, Rosenfeld SS et al. Abstract and Poster at ASCO Annual Meeting, 2009.
- TM601, a Peptide That Binds Annexin A2, Causes Regression of Choroidal Neovascularization (CNV).
Formica R, Shen J, Gong YY et al. Abstract and Poster at ARVO Annual Meeting, 2009.
- 64Cu Labeled Chlorotoxin as a Potential Imaging Agent for Glioma.
Ferdani R, Zheleznyak A, Jacoby DB, Sentissi A, Sherman C, Anderson CJ. Presentation given at the 18th International Symposium on Radiopharmaceutical Sciences, 2009.
- A phase I evaluation of intravenous (IV) 131I-chlorotoxin delivery to solid peripheral and intracranial tumors.
Gribbin TE, Senzer N, Raizer JJ et al. Abstract at ASCO Annual Meeting, 2009.
- Dosimetry evaluation in a phase I study of intravenous 131I-TM601 in patients with recurrent or refractory somatic and/or cerebral metastatic solid tumors.
Shen S, Fiveash J, Raizer J et al. Abstract and Oral Presentation at SNM Annual Meeting, 2009.
- Dosimetry study of a phase II multiple-dose intracavitary administration of 131I-TM601 in adult patients with recurrent high-grade glioma.
Shen S, Nabors LB, Raizer JJ et al. Abstract at ASCO Annual Meeting, 2009.
- Clathrin-mediated entry and cellular localization of chlorotoxin in human glioma
Wiranowska M, Colina LO, Johnson JO, Jacoby DB. Abstract at AACR Annual Meeting, 2009
- Tumor specific targeting of intravenous 131I-Chlorotoxin (131I-TM601) in patients with metastatic melanoma.
Fiveash JB, Conry RM, Shen S. Abstract at ASCO Annual Meeting, 2008.
- Potent anti-angiogenesis efficacy of chlorotoxin and its synergistic interactions with anti-VEGF therapeutic targets
Mousa SA, Jacoby DB, Dyskin E, et al. Presented at AACR Annual Meeting, 2008.
- Interim efficacy analysis of a Phase 2 study of intracavitary 131I-TM601 in patients with recurrent malignant glioma.
Nabors LB, Fiveash JB, Archambault WT, O'Neill AM. Presented at SNO Annual Meeting, 2007.
- Tumor specific targeting of intravenous 131I-Chlorotoxin (131I-TM601) in patients with recurrent glioma.
Fiveash JB, Nabors LB, Raizer JJ, Avgeropoulos N, Modarresifar H, Shen S. Presented at ASTRO Annual Meeting, 2007.
- Safety and tolerance of multiple weekly intracavitary injections of I-chlorotoxin (TM601): Preliminary results of a prospective clinical trial in patients with recurrent glioblastoma multiforme.
Fiveash JB, Nabors LB, Mamelak AN, et al. J Clin Oncol. ASCO Annual Meeting Proceedings Part I. 2006; 24 (18S):1555.
- Dosimetry of Phase I/II study of intracavitary administered 131I-TM601 peptide in patients with recurrent high-grade glioma.
Shen S, Mamelak AN, Raubitschek A, et al. Presented at ASTRO Annual Meeting, 2004.
- A Phase I/II Clinical Trial for Adult Recurrent Glioma Using I-TM601, an Iodinated Peptide Derived from Scorpion Venom Which Targets a Receptor Found on Tumor Cells
Alvarez VL, Mamelak AN, Raubitschek A, et al. Presented at the Advances in the Application of Monoclonal Antibodies. Clinical Oncology Conference. Anassa Hotel, Latchi, Cyprus. June 30th - July 2nd, 2003.
